Ghelichi-Ghojogh Mousa, Maghsoudloo Sedighe, Moftakhar Leila, Delavari Sahar, Kabootari Maryam, Sedighi Sima, Amirkhanlou Saeid
Neonatal and Children's Research Center, Department of Biostatistics and Epidemiology, School of Health, Faculty of Health, Golestan University of Medical Sciences, Gorgan, Iran.
Golestan University of Medical Sciences, Gorgan, Iran.
Ann Med Surg (Lond). 2025 May 21;87(6):3229-3235. doi: 10.1097/MS9.0000000000003283. eCollection 2025 Jun.
This study aimed to assess the impact of vitamin K supplementation on bone factors in hemodialysis patients.
In this randomized clinical trial, 80 patients with end-stage renal disease undergoing hemodialysis, aged over 18 years, and who had been on chronic dialysis for at least 1 month without taking warfarin, underwent blood tests for bone factors. Subsequently, patients were randomly assigned to either the treatment or control group using block randomization. The effects of vitamin K on bone activity markers were evaluated in both groups. Data collected were analyzed using SPSS-24 after encoding and entry.
The study comprised 41 patients in the treatment group and 39 in the control group. The average age was 53.17 ± 9.88 years in the treatment group and 54.61 ± 10.71 years in the control group. There was a significant difference in the mean albumin levels post-supplementation between the treatment (4.62 ± 0.47) and control groups (4.78 ± 0.51) ( = 0.024). Additionally, significant differences were noted in the serum levels of all bone markers (albumin, calcium, phosphorus, alkaline phosphatase, and vitamin D) before and after treatment across different age groups under 40, 40-60 years, and over 60 years ( = 0.001).
The findings of this study indicate that supplementation with vitamin K, along with vitamin D and calcium, could lead to the fortification of bone tissue and mineralization, subsequently reducing the occurrence of fractures in dialysis patients.
本研究旨在评估补充维生素K对血液透析患者骨因子的影响。
在这项随机临床试验中，80例年龄超过18岁、接受慢性透析至少1个月且未服用华法林的终末期肾病患者接受了骨因子血液检测。随后，采用区组随机化将患者随机分为治疗组或对照组。评估两组中维生素K对骨活性标志物的影响。收集的数据在编码和录入后使用SPSS-24进行分析。
研究包括41例治疗组患者和39例对照组患者。治疗组的平均年龄为53.17±9.88岁，对照组为54.61±10.71岁。治疗组（4.62±0.47）和对照组（4.78±0.51）补充后白蛋白水平均值存在显著差异（P = 0.024）。此外，在40岁以下、40 - 60岁和60岁以上的不同年龄组中，治疗前后所有骨标志物（白蛋白、钙、磷、碱性磷酸酶和维生素D）的血清水平均存在显著差异（P = 0.001）。
本研究结果表明，补充维生素K以及维生素D和钙可导致骨组织强化和矿化，从而减少透析患者骨折的发生。
